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Rare diseases, also referred to as orphan diseas-
es, have a very low incidence and include diseas-
es that occur at a prevalence of less than 5 cases 
per 10 000 people in the overall population (1). 
New rare diseases are discovered every year, and 
some of today’s known diseases in this category 
have patient populations of fewer than a hun-
dred (2).
In a country like Croatia (population of 4.5 
million), most physicians do not see a single pa-
tient with a rare disease during their entire ca-
reer. Hematologists, pathologists, and other spe-
cialists in main hospital centers would probably 
see not more than one case in several years.
Rare diseases are mostly genetic. Many of 
them are life-threatening or chronically debili-
tating. The prevalence of rare diseases may vary 
between different populations. In some popu-
lations they may be slightly more frequent than 
in others, which is especially true for genetic, in-
fectious, or malignant diseases. For example, cys-
tic fibrosis is very rare in Asia but relatively com-
mon in Europe. Other diseases, such as many 
rare forms of cancer, have no apparent pattern 
of distribution but are simply rare in most coun-
tries. European Organization for Rare Diseases 
(EURODIS) estimates that there are between 
5000 and 8000 distinct rare diseases affecting 6-
8% of the population (3).
From a societal point of view, many patients 
and families affected by a rare disease are often 
isolated and thus vulnerable to stress. The life 
expectancy of patients with rare diseases is sig-
nificantly reduced. Many of them have disabili-
ties that may become a cause for discrimination, 
which in turn might reduce educational, profes-
sional, or social opportunities for these persons. 
The research on rare diseases is scarce. The lack 
of specific health policies and the scarcity of ex-
pertise translate into delayed appropriate diag-
nosis and difficulty of access to care.
National health care services for diagnosis, 
treatment, and care of patients with rare disease 
differ significantly in terms of their availability, 
expertise, and quality. In Croatia, most rare dis-
eases are infrequently diagnosed, and when di-
agnosed they are not given special treatment 
and attention. The awareness about rare diseas-
es remains low among Croatian physicians and 
health care system organizations. The need for 
creating an infrastructure that would enable ear-
ly access to existing treatment by establishing a 
special fund for expensive therapies has only 
rarely been recognized (4). A special fund was 
established on the principle that the society can-
not accept discrimination and the fact that cer-
tain individuals are denied the benefits of medi-
cal progress because the illness they have is rare 
or costly. The main goal of this fund is to ensure 
equal access to treatment for all such patients. 
The most striking progress was made in the field 
of lysosomal storage diseases, but gradually more 
and more diseases are included.
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Lessons learned from Anderson-Fabry 
disease
Anderson-Fabry disease is an X-linked dis-
order characterized by a deficiency of α-ga-
lactosidase (5). The incidence of the disease 
is 1:40 000 among men and 1:114 000 in the 
overall population (6). Anderson-Fabry dis-
ease is a multisystemic disorder characterized 
by an accumulation of globotriasilceramide in 
the endothelium of the hearth, kidney, brain, 
skin, and other organs. Alpha-galactosidase is 
an enzyme involved in lipid metabolism, and 
its deficiency causes lipid accumulation in 
various cells leading to cell death. The disease 
is usually diagnosed by peripheral blood sam-
pling and measurement of α-galactosidase ac-
tivity in leukocytes. Like many other genetic 
diseases, Anderson-Fabry disease is readily di-
agnosed and treated at the Zagreb University 
Hospital Center. However, due to the nature 
of the disease, some patients suffering from 
Anderson-Fabry disease had been seen by 7 to 
10 different specialists on average before a di-
agnosis was finally made (7).
One of the main characteristics of the dis-
ease is the appearance of red spots (angioker-
atomas) on the skin of the lower abdomen 
and genital regions. In early childhood, pa-
tients with Anderson-Fabry disease experi-
ence bouts of pain and/or acroparesthesia, 
recurrent febrile episodes, and heat and cold 
intolerance. An inability to sweat and corneal 
clouding is also often encountered. Older pa-
tients have the same symptoms but develop 
proteinuria followed by kidney failure. Tran-
sient ischemic attacks, cerebrovascular stroke, 
myocardial infarctions, left ventricular hyper-
trophy, and hearing loss are common compli-
cations (8,9). Without appropriate therapy, 
most patients die in the fourth to fifth decade 
of life (10).
The diagnosis of Anderson-Fabry disease 
should be considered in younger patients pre-
senting with crebrovascular stroke, left ven-
tricular hypertrophy, or kidney failure of 
unknown origin. The knowledge about An-
derson Fabry disease increased over past few 
years and today we know that women are not 
only carriers, but also the patients due to the 
random inactivation of the X-chromosome 
(11). Today, there are two effective treatment 
options – enzyme replacement therapies with 
agalsidase alpha or agalsidase beta – available 
for most patients diagnosed with Anderson-
Fabry disease (12,13). The treatment costs 
are covered by the “Expensive Drug Fund” 
of the Croatian Institute for Health Insur-
ance, which also covers the costs of treatment 
of some other rare diseases like Morbus Gau-
cher and mucopolisaharidoses and some more 
common diseases like malignant lymphoma, 
breast carcinoma, tuberculosis, AIDS, juve-
nile arthritis, colon carcinoma, multiple scle-
rosis, and others.
Successful development of the Rare 
Disease Patient Organization
The Croatian Society of Patients with Rare 
Diseases is a non-profit organization estab-
lished in November 2006 as a successor of 
the Croatian Society for Inherited Metabol-
ic Diseases, which in itself was a derivative of 
the Croatian Society for Mucopolysacchari-
doses and Similar Diseases (www.rijetke-boles-
ti.hr). The history of the Society illustrates the 
need for expanding the scope of work from 
one specific rare disease to all inherited met-
abolic diseases and, finally, to all rare diseas-
es. Members of the Society are not only pa-
tients suffering from various rare diseases, but 
also non-profit organizations (NGOs) de-
voted to particular problems of those affect-
ed by rare diseases. The Society for Rare Dis-
eases has been joined by other organizations, 
such as Association for Persons with Prader-
Willy syndrome, the Croatian Organization 
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for Cystic Fibrosis, the Croatian Organiza-
tion for Osteogenesis Imperfecta, and Dys-
trophic Epidermolysis Bullosa Research Asso-
ciation. Other established rare disease patient 
organizations are currently in the process of 
joining the Croatian Society of Patients with 
Rare Diseases. While these organizations have 
worked for years on solving various problems 
of patients with specific rare diseases, the um-
brella society provides a platform for work-
ing together as one network for rare diseases. 
As the joint efforts increased, it became essen-
tial to strengthen the cooperation with other 
non-governmental organizations. The main 
goal of the society is to improve the quality 
of life of patients suffering from rare diseas-
es and their families. The Society of Patients 
with Rare Diseases had numerous activities 
over the past two years, including the launch 
of the first rare disease Web site (www.rijetke-
bolesti.hr) bringing information about the or-
ganization, rare diseases in general, and other 
member organizations. In 2007, the Society 
organized the first local Meeting on Rare Dis-
eases, during which patients and their fam-
ily members, physicians, NGO workers, and 
government officials met and discussed essen-
tial issues concerning rare diseases. A series 
of public activities under the name “Give me 
a hand” was organized with the main goal to 
inform and educate citizens about rare diseas-
es and to raise funds for future activities. On 
February 29, 2008, the Society celebrated the 
European Rare Disease Day.
The first steps in the positive direction have 
been taken to build a health care infrastructure 
for rare diseases. Nevertheless, further progress 
is still depending on NGOs and there is still a 
need for more structural and transparent regu-
lations.
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